| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |